secwatch.observer — SEC 8-K summary
======================================

Issuer:     TuHURA Biosciences, Inc./NV (HURA)
CIK:        0001498382
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0000950170-22-024708
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 3.03, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kintara Therapeutics effects 1-for-50 reverse stock split, trading on adjusted basis Nov 14
--------------------------------------------------------------------------------

- Reverse stock split at 1:50 ratio effective 5:00 p.m. ET on November 11, 2022.
- No fractional shares issued; any fractional shares rounded up to nearest whole share.
- Common stock continues trading on Nasdaq under ticker KTRA, new CUSIP 49720K200.
- Authorized shares of common stock reduced proportionally from 50 to 1.
- Board approved the split on October 28, 2022; no stockholder vote required under Nevada law.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1498382/000095017022024708/0000950170-22-024708-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1498382/000095017022024708/ktra-20221110.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-024708

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer